Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Fig. 1

In vitro and in vivo evaluation of 68Ga/177Lu-labeled LNC1004. a Growth curves of tumors in mice following implantation of either MC38 or CT26 cells compared with those co-implanted with NIH3T3-FAP cells (n = 5/group). b FAP expression in MC38, CT26, and NIH3T3-FAP cells determined using western blotting. c Cell uptake assay of 68Ga-LNC1004 on MC38, CT26, NIH3T3-FAP, MC38/NIH3T3-FAP, and CT26/NIH3T3-FAP cells. This assay was complemented with a blocking experiment to validate specificity (n = 3/group). d Representative static PET images of 68Ga-LNC1004 in MC38/NIH3T3-FAP and CT26/NIH3T3-FAP tumor-bearing mice (n = 3/group). e PET quantification data for 68Ga-LNC1004 in MC38/NIH3T3-FAP and CT26/NIH3T3-FAP tumor-bearing mice (n = 3/group). f, g SPECT MIP images and biodistribution data of 177Lu-LNC1004 from 4 to 144 h after injection in mice with MC38/NIH3T3-FAP and CT26/NIH3T3-FAP tumor models (n = 3/group)

Back to article page